Corteva Reports Third-Quarter 2026 Results; Updates FY 2026 Outlook
Corteva, Inc. (CTVA) filed an SEC Form 8-K — Results of Operations and Financial Condition. News Release Corteva Reports Third-Quarter 2026 Results; Updates FY 2026 Outlook • Third-quarter results reflect strong new product sales growth and continued operational excellence, helping mitigate broader market headwinds • Pricing pressure was concentrated in North America an
How this was made
The 30-second read
Why it matters
The updated guidance reflects weaker market conditions in Brazil, leading to a modest decline in net sales and a GAAP loss, which may trigger sell pressure.
Market read
Earnings miss and updated guidance are likely to depress CTVA stock in the near term, while sector peers may experience similar sentiment.
What to watch
Strong new‑product sales and resilient growth in EMEA and Asia‑Pacific may offset the Brazil weakness over the longer term.
Corteva reports Q3 2026 net sales down 9% and a GAAP loss from continuing operations; cuts full-year Adjusted Pro Forma Operating EBITDA outlook on weaker Brazil market
Third-quarter net sales fell 9%, Adjusted Pro Forma Operating EBITDA fell 17%, and pro forma GAAP income from continuing operations was a $(54) million loss against $60 million a year earlier. Year-to-date Adjusted Pro Forma Operating EBITDA was flat and Operating EPS rose 49%, and the filing reports organic growth in North America, EMEA and Asia Pacific. The company updated full-year guidance because of a weaker Brazil market.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Net sales, 3Q 2026GAAP | $1.59B | – | (9)% |
| Organic sales, 3Q 2026non-GAAP | $1.58B | – | (9)% |
| Pro forma GAAP income (loss) from continuing operations after income taxes, 3Q 2026GAAP | −$54M | – | (190)% |
| Pro forma GAAP EPS, 3Q 2026GAAP | $(0.08) | – | (189)% |
| Adjusted Pro Forma Operating EBITDA, 3Q 2026non-GAAP | $222M | – | (17)% |
| Adjusted Pro Forma Operating EPS, 3Q 2026non-GAAP | $0.06 | – | (57)% |
| Volume change, 3Q 2026other | (2)% | – | – |
| Price change, 3Q 2026other | (7)% | – | – |
| Net sales, nine months 2026 (YTD)GAAP | $5.36B | – | (1)% |
| Organic sales, nine months 2026 (YTD)non-GAAP | $5.2B | – | (4)% |
| Volume change, nine months 2026 (YTD)other | Flat | – | – |
| Price change, nine months 2026 (YTD)other | (4)% | – | – |
| Pro forma GAAP income from continuing operations after income taxes, nine months 2026 (YTD)GAAP | $112M | – | (68)% |
| Pro forma GAAP margin, nine months 2026 (YTD)GAAP | 2.1% | – | – |
| Pro forma GAAP EPS from continuing operations, nine months 2026 (YTD)GAAP | $0.16 | – | (68)% |
| Adjusted Pro Forma Operating EBITDA, nine months 2026 (YTD)non-GAAP | $943M | – | 0% |
| Adjusted Pro Forma Operating EBITDA margin, nine months 2026 (YTD)non-GAAP | 17.6% | – | Expanded 30 basis points |
| Adjusted Pro Forma Operating EPS, nine months 2026 (YTD)non-GAAP | $0.76 | – | 49% |
Segments
| Segment | Revenue | q/q | y/y |
|---|---|---|---|
| North America (U.S. and Canada), 3Q 2026Filing reports 7% organic sales growth, with volume up 19% as new product growth and early demand more than offset pricing headwinds in U.S. acetochlor. Prior-year segment revenue $537 million as printed. | $574M | – | 7% |
| EMEA (Europe, Middle East and Africa), 3Q 2026Filing reports 14% organic sales growth, driven by strong demand for new and differentiated products while holding price flat. Prior-year segment revenue $213 million as printed. | $239M | – | 12% |
| Latin America, 3Q 2026Filing reports organic sales decline of 31%, reflecting challenging market dynamics in Brazil. Volumes decreased 24% due to elevated channel inventory and delayed purchasing given farmer liquidity constraints and high interest rates, which the company cites as the explanation. Price declined 7% amid competitive pressure on mature molecules. Prior-year segment revenue $791 million as printed. | $570M | – | (28)% |
| Asia Pacific, 3Q 2026Filing reports 5% organic sales growth, led by strong demand for new products, which supported 7% volume growth. Price declined 2% due to a competitive market environment. Prior-year segment revenue $201 million as printed. | $208M | – | 3% |
| North America (U.S. and Canada), nine months 2026 (YTD)Filing prints YTD organic change as -%. Prior-year segment revenue $1,821 million as printed. | $1.83B | – | -% |
| EMEA (Europe, Middle East and Africa), nine months 2026 (YTD)Filing prints YTD organic change of 1%. Prior-year segment revenue $1,345 million as printed. | $1.44B | – | 7% |
| Latin America, nine months 2026 (YTD)Filing prints YTD organic change of (18)%. Prior-year segment revenue $1,601 million as printed. | $1.40B | – | (12)% |
| Asia Pacific, nine months 2026 (YTD)Filing prints YTD organic change of 7%. Prior-year segment revenue $652 million as printed. | $690M | – | 6% |
FY 2026 (updated) outlook
- NoteAdjusted Pro Forma Operating EBITDA (non-GAAP): $1.1 billion to $1.125 billion
- NoteAdjusted Pro Forma Operating EPS (non-GAAP): $0.76 to $0.80 per share
- NoteNet pre-tax restructuring charges during 2026 for Crop Protection network optimization: approximately $130 million to $140 million, with activities expected to be substantially complete in 2028
- NoteCompany does not provide a reconciliation of forward-looking non-GAAP measures to the most comparable GAAP measures
Capital returns
- Board of Directors authorized the first common dividend since the spin. The release does not print the dividend amount, the record date or the payment date.
What drove it
- Company states that new product sales growth and continued operational excellence helped mitigate broader market headwinds in the third quarter.
- Company states that pricing pressure was concentrated in North America and Latin America, reflecting an anticipated acetochlor headwind and competitive dynamics on molecules late in their lifecycle, respectively.
- Company states that North America volume rose 19% as new product growth and early demand more than offset pricing headwinds in U.S. acetochlor.
- Company states that EMEA organic sales growth of 14% was driven by strong demand for new and differentiated products while holding price flat.
- Company states that Latin America volume fell 24% due to elevated channel inventory and delayed purchasing given farmer liquidity constraints and high interest rates.
- Company reports that Adjusted Pro Forma Operating EBITDA margin for 3Q 2026 eroded 140 basis points, and that Pro Forma GAAP income from continuing operations margin declined 680 basis points.
- Company reports that year-to-date Adjusted Pro Forma Operating EBITDA margin expanded 30 basis points to 17.6%.
Concerns
- Latin America organic sales declined 31% in 3Q 2026, with volume down 24% and price down 7%.
- Company describes Brazil as materially weaker than anticipated and states that Crop Protection market conditions have become more challenging, with a significantly softer market than previously anticipated.
- Pro forma GAAP income from continuing operations was a loss of $(54) million in 3Q 2026, against income of $60 million in 3Q 2025.
- Pricing declined 7% in 3Q 2026, driven by competitive pressure on molecules late in their lifecycle in Brazil and U.S. acetochlor.
- Company updated full-year 2026 guidance, primarily reflecting the deterioration in Brazil, and expects net pre-tax restructuring charges of approximately $130 million to $140 million during 2026.
What to watch
- Brazil market conditions, including farmer liquidity, financing costs, channel inventory and purchasing patterns, given the company's updated full-year outlook.
- Whether full-year Adjusted Pro Forma Operating EBITDA lands within the $1.1 billion to $1.125 billion range and Adjusted Pro Forma Operating EPS within $0.76 to $0.80.
- U.S. acetochlor pricing, which the CEO says was consistent with the company's expectations.
- Progress of new product sales and the North America and EMEA volume growth the company cites.
- Pace of Crop Protection network optimization and the 2026 restructuring charges, with activities expected to be substantially complete in 2028.
- Amount and timing of the first common dividend, which the release does not quantify.
Balance sheet and cash flow
- The release does not print cash, debt, total assets, total equity, operating cash flow or free cash flow in the documents provided.
Analysis
Corteva's third quarter 2026 shows a sharp contrast between the company's core regions and Latin America. Net sales fell 9% to $1,591 million and organic sales fell 9%. Within that, North America organic sales rose 7% with volume up 19%, and EMEA organic sales rose 14% with price flat. Latin America organic sales fell 31% as volume dropped 24% and price fell 7%. The company attributes the Latin America decline to elevated channel inventory, delayed purchasing, farmer liquidity constraints and high interest rates. Asia Pacific organic sales grew 5%, with volume up 7% and price down 2%.
Profitability weakened more than sales. Pro forma GAAP income from continuing operations was $(54) million, against $60 million a year earlier, and pro forma GAAP EPS was $(0.08). Adjusted Pro Forma Operating EBITDA was $222 million, down 17% from $268 million, and the filing states that Adjusted Pro Forma Operating EBITDA margin eroded 140 basis points in the quarter. Adjusted Pro Forma Operating EPS was $0.06, down 57%. The company does not print a third-quarter margin figure for these measures in the documents provided.
On a nine-month basis, the picture is steadier. Net sales were $5,357 million, down 1%, and organic sales were down 4%, with volume flat and price down 4%. Adjusted Pro Forma Operating EBITDA was $943 million, essentially flat against $937 million, and the margin expanded 30 basis points to 17.6%. Adjusted Pro Forma Operating EPS was $0.76, up 49% as printed. Year-to-date pro forma GAAP income from continuing operations was $112 million, down 68%, and GAAP EPS from continuing operations was $0.16, also down 68%. The year-to-date regional table shows EMEA net sales up 7% and Asia Pacific up 6%, while Latin America was down 12%.
For the full year, the company updated its outlook, citing weaker market conditions than previously anticipated in Brazil. Adjusted Pro Forma Operating EBITDA is now expected at $1.1 billion to $1.125 billion, and Adjusted Pro Forma Operating EPS at $0.76 to $0.80 per share. The release does not print the prior guidance ranges, so this read cannot confirm the size of the change. The company also expects net pre-tax restructuring charges of approximately $130 million to $140 million in 2026 for optimizing its Crop Protection manufacturing and external partner network, with the work expected to be substantially complete in 2028.
Capital allocation is limited to one disclosure: the board authorized the first common dividend since the spin, with no amount, record date or payment date printed. The release contains no cash, debt, cash flow or balance sheet totals, so the read on liquidity and leverage is not possible from this document. The figures that deserve attention are the third-quarter Latin America decline, the swing to a GAAP loss, the 17% fall in quarterly Adjusted Pro Forma Operating EBITDA, and whether the reduced full-year range can absorb the Brazil weakness.
Management, verbatim
“We executed well against the things we can control. New products performed strongly, productivity delivered, and we generated broad- based organic growth outside Latin America. The pressure remains concentrated. Acetochlor pricing in the U.S. was consistent with our expectations, but Brazil was materially weaker than anticipated. While those conditions are reflected in our updated outlook, our strategy has not changed. Innovation, productivity and disciplined execution remain the foundation for sustainable long-term growth.”
Luke Kissam, CEO
Not in the filing
stated, not guessed- Prior-year pro forma GAAP EPS from continuing operations for 3Q 2025
- Prior-year Adjusted Pro Forma Operating EPS for 3Q 2025
- Organic sales prior-year dollar figure for 3Q 2025 and nine months 2025
- Adjusted Pro Forma Operating EBITDA margin for 3Q 2026 and 3Q 2025 as values
- Adjusted Pro Forma Operating EBITDA margin prior-year value for nine months 2025
- Pro forma GAAP income from continuing operations prior-year figure for nine months 2025
- Pro forma GAAP EPS prior-year figure for nine months 2025
- Prior-year Adjusted Pro Forma Operating EPS for nine months 2025
- Prior guidance ranges for FY 2026 Adjusted Pro Forma Operating EBITDA and Operating EPS, needed to judge whether guidance was lowered
- Revenue, gross margin, operating expense and tax rate guidance
- Cost of sales, gross margin, R&D, SG&A and restructuring line items in GAAP statements
- Interest expense, income tax and net income lines in the GAAP statements
- Cash, debt, total assets and total equity
- Operating cash flow, free cash flow and capital expenditures
- Share repurchases and dividend amount, record date and payment date
- Regional price and volume for North America and EMEA year-to-date
- Share price reaction and analyst consensus, which the documents do not contain
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
Corteva, a NYSE‑listed crop‑protection company, filed its Form 8‑K with Q3 2026 results and revised FY 2026 outlook.
Ticker impact
Corteva reported Q3 2026 results and updated FY 2026 outlook with lower sales and earnings guidance.
likely pressure as the market prices in the updated guidance
The earnings release shows a 9% drop in net sales YoY and a GAAP loss, prompting investors to reassess valuation.
Market effects
Crop protection sector may see broader pressure as Brazil market weakness is highlighted.
Latin America exposure could weigh on regional agribusiness stocks.
Limited to agricultural inputs; unlikely to affect broader indices.
Counterpoint
If the market overreacts to the guidance downgrade, the stock could be a short‑term buying opportunity.
Key entities
- companyCorteva, Inc.
Global crop‑protection firm reporting Q3 2026 results.
